Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Post by sjaakon Feb 03, 2002 11:34am
1443 Views
Post# 4726735

followup on patients

followup on patientsIthno I talked to Doug Ball 2-3 weeks ago and I posted my comments on this board. I also asked him the same question you asked in your recent post and got the same answer. At the time I was also puzzled but did not think too much of it because I was talking to the CFO and thought perhaps he might be out of the loop on technical issues. I agree with you that onc has to know about who survived, regardless of whether they stopped formally monitoring the patients. The Baker Clinic is not that big a place and it defies logic that onc would not be aware of whether any patient enrolled was alive or not. I also accept that patients could die for many reasons, but they must know whether they are alive or dead. So the question is: why did we both not get a straighforward answer. The answer could be that whatever the result, this would in fact be signicant news which they may not want to release at this time, but, then would it not have been better to be up front about it by saying that it will be released with the news release that is forthcoming about the results on efficacy. Anyone have any other comments?
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse